SCHEMBL1403255

SCHEMBL1403255

O=C(C=Cc1ccccc1NS(=O)(=O)c1ccccc1)NO

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 15/20 0.64
HDAC6 Q9UBN7 14/20 0.64
HDAC1 Q13547 14/20 0.64
HDAC3 O15379 12/20 0.64
HDAC4 P56524 12/20 0.64
HDAC2 Q92769 12/20 0.64
HDAC7 Q8WUI4 11/20 0.64
HDAC10 Q969S8 11/20 0.64
HDAC11 Q96DB2 11/20 0.64
HDAC9 Q9UKV0 11/20 0.64
HDAC5 Q9UQL6 11/20 0.64
SNCA P37840 1/20 0.55
BRD4 O60885 1/20 0.55
ESR1 P03372 1/20 0.55
PTGS1 P23219 1/20 0.55
PDE4A P27815 1/20 0.55
PIK3CA P42336 1/20 0.55
HTR6 P50406 1/20 0.55
PDE4D Q08499 1/20 0.55
ASPH Q12797 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8770044 0.91 HDAC8 (0.56) HDAC8HDAC6HDAC1HDAC3HDAC4
SCHEMBL8770040 0.91 HDAC8 (0.56) HDAC8HDAC6HDAC1HDAC3HDAC4
SCHEMBL8770110 0.89 HDAC8 (0.55) HDAC8HDAC6HDAC1HDAC3HDAC4
SCHEMBL8770106 0.89 HDAC8 (0.55) HDAC8HDAC6HDAC1HDAC3HDAC4
SCHEMBL8120286 0.87 SNCA (0.56) HDAC8HDAC6HDAC1HDAC3HDAC4
SCHEMBL8120283 0.87 SNCA (0.56) HDAC8HDAC6HDAC1HDAC3HDAC4
SCHEMBL18069271 0.86 HDAC1 (0.67) HDAC8HDAC6HDAC1HDAC3HDAC4
SCHEMBL8991816 0.84 HDAC1 (0.59) HDAC8HDAC6HDAC1HDAC3HDAC4
SCHEMBL8991817 0.84 HDAC1 (0.59) HDAC8HDAC6HDAC1HDAC3HDAC4
SCHEMBL18045875 0.83 HDAC1 (0.69) HDAC8HDAC6HDAC1HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2292593-A2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TopoTarget UK Limited (GB) 2011-03-09 EP disclosed
US-7557140-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2009-07-07 US disclosed
US-7407988-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2008-08-05 US disclosed
US-20080161401-A1 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS TOPOTARGET UK LIMITED (GB) 2008-07-03 US disclosed
US-7183298-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2007-02-27 US disclosed
US-20070004806-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2007-01-04 US disclosed
US-20050107445-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors PROLIFIX LIMITED (GB) 2005-05-19 US disclosed
US-6888027-B2 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPOTARGET UK LIMITED (GB) 2005-05-03 US disclosed
US-20050085515-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors TOPO TARGET UK LIMITED, (GB) 2005-04-21 US disclosed
US-20040077726-A1 Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors SWK FUNDING LLC 2004-04-22 US disclosed
EP-1328510-A2 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS PROLIFIX LTD. (GB) 2003-07-23 EP disclosed
WO-2002030879-A2 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS PROLIFIX LIMITED (GB) 2002-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107445-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors HDAC1, HDAC11, HDAC3 HDAC8 4/4885HDAC6 10/4885HDAC1 1/4885
US-20070004806-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors HDAC1, HDAC11, HDAC3 HDAC8 4/4885HDAC6 10/4885HDAC1 1/4885
US-20080161401-A1 CARBAMIC ACID COMPOUNDS COMPRISING A SULFONAMIDE LINKAGE AS HDAC INHIBITORS HDAC1, HDAC11, HDAC3 HDAC8 4/4885HDAC6 10/4885HDAC1 1/4885
US-20040077726-A1 Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors HDAC1, HDAC11, HDAC2 HDAC8 4/4885HDAC6 10/4885HDAC1 1/4885
US-20050085515-A1 Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors HDAC1, HDAC11, HDAC3 HDAC8 4/4885HDAC6 10/4885HDAC1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.